Bone marrow-derived mesenchymal stem cells (BM-MSCs) are the most well-studied and characterised stem cell types. This review was undertaken of the current available phase II/III randomised clinical trials (RCTs) that delivered BM-MSCs to treat patients with cardiomyopathy, and to assess their performance.
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed during the systematic review and meta-analysis. Eligible studies were reviewed, and their data charted. To assess the efficacy of BM-MSCs, the outcome was improvement in left ventricular ejection fraction (LVEF) and 6-minute walking distance (6MWD).
The pooled weighted mean difference (WMD) showed that BM-MSCs treatment improved the 6MWD by 27.86 m (95% CI 0.11–55.6 m) compared with the control groups. The pooled WMD showed that BM-MSCs treatment improved the LVEF by 6.37% (95% CI 5.48%–7.26%) compared with the control groups.
BM-MSCs treatment is an effective intervention for managing patients with heart failure, but it requires larger and more robust clinical trials to support its routine use in clinics.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Heart disease and stroke statistics-2022 update: A report from the American Heart Association.Circulation. 2022; 145: e153-e639
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013; 62: e147-e239
- Cell death in the pathogenesis and progression of heart failure.Heart Failure Rev. 2016; 21: 117-121
- Cardiomyocyte proliferation: teaching an old dogma new tricks.Circ Res. 2017; 120: 627-629
- Mesenchymal stem cells for cardiac repair.in: Haider K.H. Handbook of Stem Cell Therapy. Springer Nature Singapore, Singapore2022: 1-53
- Preclinical studies of stem cell therapy for heart disease.Circ Res. 2018; 122: 1006-1020
- Bone marrow stem cell transplantation for cardiac repair.Am J Physiol Heart Circ Physiol. 2005; 288: H2557-H2567
- 7.in: Haider K.H. Adrenomedullins and their emerging role in regenerative medicine stem cells: from myth to reality and evolving. De Gruyter, 2019: 145-165
- Bone marrow cell therapy, and cardiac reparability: better cell characterization will enhance clinical success.Regen Med. 2018; 13: 457-475
- Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results.Jpn Circ J. 2001; 65: 845-847
- Mesenchymal stem cells current clinical applications: a systematic review.Arch Med Res. 2021; 52: 93-101
- Long-term results of intracardiac mesenchymal stem cell transplantation in patients with cardiomyopathy.Circ J. 2019; 83: 1590-1599
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann Intern Med. 2009; 151 (264-9, w64)
- Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data.Behav Modif. 2017; 41: 323-339
- Assessing the quality of reports of randomized clinical trials: is blinding necessary?.Control Clin Trials. 1996; 17: 1-12
- The six-minute walk test.Respir Care. 2003; 48: 783-785
- Measuring inconsistency in meta-analyses.BMJ (Clin Res Ed). 2003; 327: 557-560
- A new improved graphical and quantitative method for detecting bias in meta-analysis.Int J Evid Based Healthc. 2018; 16: 195-203
- Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.JAMA. 2012; 308: 2369-2379
- A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure.Circ Res. 2015; 117: 576-584
- Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics.J Am Coll Cardiol. 2013; 61: 2329-2338
- Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).Eur Heart J. 2015; 36: 1744-1753
- Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.JAMA. 2014; 311: 62-73
- A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy.Int Heart J. 2017; 58: 238-244
- A systematic review and meta-analysis: safety and efficacy of mesenchymal stem cells therapy for heart failure.Curr Stem Cell Res Ther. 2021; 16: 354-365
- Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis.Stem Cell Res Ther. 2019; 10: 150
- Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species.Front Cell Dev Biol. 2021; 9
- Effect of stem cell transplantation on patients with ischemic heart failure: a systematic review and meta-analysis of randomized controlled trials.Stem Cell Res Ther. 2019; 10: 125
- Cell therapy for nonischemic dilated cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.Stem Cells Transl Med. 2021; 10: 1394-1405
- Effects of stem cells on non-ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.Cytotherapy. 2020; 22: 699-711
- Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.Circ Res. 2015; 116: 1346-1360
- Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials.Stem Cell Res Ther. 2021; 12: 600
- 6-minute walking test: a useful tool in the management of heart failure patients.Ther Adv Cardiovasc Dis. 2019; 13 (1753944719870084)
- Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review.Eur Heart J. 2005; 26: 778-793
- Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.Contemp Clin Trials. 2021; 100: 106227
- Prognostic value of 6-minute walk test in stable outpatients with heart failure.Tex Heart Inst J. 2007; 34: 166-169
- Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials.J Am Coll Cardiol. 2016; 68: 2690-2707
- Mesenchymal stem cell therapy for ischemic heart disease: systematic review and meta-analysis.Int J Stem Cells. 2018; 11: 1-12
- Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study).Circ Res. 2017; 121: 1279-1290
Shahid MS, Lasheen W, Haider KH. Modest outcome of clinical trials with bone marrow cells for myocardial repair: is the autologous source of cells the prime culprit? J Thorac Dis. 2916;8(10):E1371–E1374.
- Hematopoietic stem cell transplantation: the quality matters.J Stem Cell Res Ther. 2017; 7: 6
- The aging stem cells and cardiac reparability: lesson learnt from clinical studies is that old is not always gold.Regen Med. 2018; 13: 457-475
Published online: March 03, 2023
Accepted: January 2, 2023
Received in revised form: December 22, 2022
Received: June 22, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.